Edward Ludwig Buys 5,000 Shares of Boston Scientific (NYSE:BSX) Stock

Boston Scientific Corporation (NYSE:BSX) Director Edward Ludwig acquired 5,000 shares of the business’s stock in a transaction dated Friday, July 31st. The stock was purchased at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the acquisition, the director directly owned 30,359 shares in the company, valued at approximately $1,380,727.32. This represents a 19.72% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $49.14 on Wednesday. The stock’s 50-day moving average is $45.78 and its 200 day moving average is $61.39. The stock has a market cap of $73.04 billion, a price-to-earnings ratio of 19.90, a P/E/G ratio of 1.06 and a beta of 0.56. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The business had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.36%. The business’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period last year, the business earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, sell-side analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific declared that its board has approved a stock buyback program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s management believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on BSX shares. The Goldman Sachs Group set a $71.00 price target on Boston Scientific in a research note on Thursday, May 28th. BTIG Research cut their target price on shares of Boston Scientific from $65.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, July 29th. UBS Group lowered their price target on shares of Boston Scientific from $74.00 to $67.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Raymond James Financial reissued an “outperform” rating and set a $57.00 price target on shares of Boston Scientific in a research report on Thursday, July 30th. Finally, Argus reaffirmed a “hold” rating on shares of Boston Scientific in a research note on Friday, July 31st. Twenty-four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and an average target price of $71.62.

Institutional Trading of Boston Scientific

Several large investors have recently bought and sold shares of BSX. Brighton Jones LLC grew its stake in Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after purchasing an additional 226 shares during the period. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific in the 2nd quarter worth approximately $26,000. Main Street Financial Solutions LLC grew its stake in shares of Boston Scientific by 35.3% in the second quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock worth $812,000 after acquiring an additional 1,971 shares during the last quarter. Ieq Capital LLC increased its holdings in shares of Boston Scientific by 97.0% during the second quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock valued at $13,275,000 after acquiring an additional 60,860 shares in the last quarter. Finally, HUB Investment Partners LLC raised its position in shares of Boston Scientific by 56.2% in the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock worth $763,000 after purchasing an additional 2,556 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.